David Toro-Tobón1, Dedsy Berbesi-Fernandez2, Pedro Mateu-Gelabert3, Ángela M Segura-Cardona4, Liliana P Montoya-Vélez5. 1. School of Medicine, CES University, Medellin, Colombia; Epidemiology and Bioestatistics Research Group, CES University, Medellin, Colombia. Electronic address: davidtorot@outlook.com. 2. Epidemiology and Bioestatistics Research Group, CES University, Medellin, Colombia; School of Nursing, CES University, Medellin, Colombia. Electronic address: dberbesi@ces.edu.co. 3. National Development and Research Institutes, New York City, New York, USA. Electronic address: mateu-gelabert@ndri.org. 4. School of Medicine, CES University, Medellin, Colombia; Epidemiology and Bioestatistics Research Group, CES University, Medellin, Colombia. Electronic address: asegura@ces.edu.co. 5. School of Medicine, CES University, Medellin, Colombia; Division of Public Health, CES University, Medellin, Colombia. Electronic address: lmontoya@ces.edu.co.
Abstract
BACKGROUND: Colombia has a growing population of young people who inject drugs (PWID). Despite the previously reported association of injection drug use with hepatitis c virus (HCV) in other countries, studies on HCV prevalence in PWID in Colombia are lacking. The objective of this study is to determine the prevalence, demographics, and correlations of risky injection behaviours in HCV seropositive PWID in four Colombian cities (Armenia, Bogotá, Cúcuta and Pereira). METHODS: This was a cross-sectional study carried out between January and June of 2014 that included 918 PWID from four Colombian cities, recruited by Respondent Driven Sampling. A survey was administered to each participant, and blood samples were collected. Binary logistic regression and multivariate analyses for each city were conducted. RESULTS: Average participant age was 26 years (SD 6.5). Of all participants, 27.3% of PWID were HCV seropositive, of which 52% were 25 years old or younger. In Pereira, increased risk of HCV infection was found for PWID that: had a history of injection drug use of 5 years or more (AOR: 3.0, CI: 1.7-7.8); were between 25 and 28 years of age (AOR: 5.2, CI: 1.0-26.3); had higher injection frequency (AOR: 2.5, CI: 1.4-4.2), and daily use of gifted, sold, or rented needles or syringes (AOR: 4.5, CI: 1.0-7.1). Additionally, in Cucuta, being HIV seropositive appeared to be greatly associated with risk of HCV seropositivity (AOR: 16.9, CI: 3.5-81.5). CONCLUSION: Although prevalence of HCV in PWID in Colombia is lower than that reported for other countries, the described demographic characteristics and diverse risky injection behaviors on each city, in the context of a young PWID population with a short injection drug use history, should be taken into account in order to guide efforts towards preventing and reducing risk of HCV infection in PWID in Colombia.
BACKGROUND: Colombia has a growing population of young people who inject drugs (PWID). Despite the previously reported association of injection drug use with hepatitis c virus (HCV) in other countries, studies on HCV prevalence in PWID in Colombia are lacking. The objective of this study is to determine the prevalence, demographics, and correlations of risky injection behaviours in HCV seropositive PWID in four Colombian cities (Armenia, Bogotá, Cúcuta and Pereira). METHODS: This was a cross-sectional study carried out between January and June of 2014 that included 918 PWID from four Colombian cities, recruited by Respondent Driven Sampling. A survey was administered to each participant, and blood samples were collected. Binary logistic regression and multivariate analyses for each city were conducted. RESULTS: Average participant age was 26 years (SD 6.5). Of all participants, 27.3% of PWID were HCV seropositive, of which 52% were 25 years old or younger. In Pereira, increased risk of HCV infection was found for PWID that: had a history of injection drug use of 5 years or more (AOR: 3.0, CI: 1.7-7.8); were between 25 and 28 years of age (AOR: 5.2, CI: 1.0-26.3); had higher injection frequency (AOR: 2.5, CI: 1.4-4.2), and daily use of gifted, sold, or rented needles or syringes (AOR: 4.5, CI: 1.0-7.1). Additionally, in Cucuta, being HIV seropositive appeared to be greatly associated with risk of HCV seropositivity (AOR: 16.9, CI: 3.5-81.5). CONCLUSION: Although prevalence of HCV in PWID in Colombia is lower than that reported for other countries, the described demographic characteristics and diverse risky injection behaviors on each city, in the context of a young PWID population with a short injection drug use history, should be taken into account in order to guide efforts towards preventing and reducing risk of HCV infection in PWID in Colombia.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Carmen L R Lopes; Sheila A Teles; Márcia P Espírito-Santo; Elisabete Lampe; Fabiana P Rodrigues; Ana Rita C Motta-Castro; Thaís A Marinho; Nádia R Reis; Agabo M C Silva; Regina M B Martins Journal: Rev Saude Publica Date: 2009-08 Impact factor: 2.106
Authors: M Hickman; V Hope; T Brady; P Madden; S Jones; S Honor; G Holloway; F Ncube; J Parry Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: Nicky McCreesh; Andrew Copas; Janet Seeley; Lisa G Johnston; Pam Sonnenberg; Richard J Hayes; Simon D W Frost; Richard G White Journal: PLoS One Date: 2013-10-31 Impact factor: 3.240
Authors: David A Rolls; Rachel Sacks-Davis; Rebecca Jenkinson; Emma McBryde; Philippa Pattison; Garry Robins; Margaret Hellard Journal: PLoS One Date: 2013-11-01 Impact factor: 3.240